Skip to main content
Top

Open Access 09-05-2024 | Hepatitis B | Research

Occult hepatitis B infection in children born to HBeAg-positive women confers a low long-term risk for HBsAg-positive infection

Authors: Anders Eilard, Maria E. Andersson, Rune Wejstål, Gunnar Norkrans, Magnus Lindh

Published in: Infection

Login to get access

Abstract

Purpose

Mother-to-child transmission (MTCT) has been the main cause of chronic hepatitis B virus (HBV) infection, particularly in East Asia. Hepatitis B immunoglobulin (HBIG) and vaccination given directly after birth effectively prevents hepatitis B surface antigen (HBsAg)-positive (overt) HBV infection, but occult hepatitis B infection (OBI) may develop despite adequate prophylaxis. The aim of this study was to investigate the long-term outcome in children born to mothers with very high HBV DNA levels with special focus on children discovered in early childhood with OBI.

Methods

One-year and long-term outcome regarding overt and occult HBV infection were analysed in 66 children born to hepatitis B e antigen (HBeAg)-positive mothers, and were compared with one-year outcome in 69 children born to HBeAg-negative mothers. The children were born between 1998 and 2018.

Results

Six children born to HBeAg-positive mothers developed overt chronic HBV infection, in two cases after normal pregnancies and despite HBIG and vaccination, but never when nucleotide analogue treatment was given during pregnancy. OBI with HBV DNA detected in serum in the absence of surface antigen (HBsAg) was observed in four children at the age of 1 year. One of them was transiently HBsAg-positive at the age of 7 years. At long-term follow-up, six children had overt chronic infection, one had OBI and six had previous OBI or positive anti-HBc suggesting resolved unidentified infections.

Conclusion

The results indicate that children born to mothers with high HBV DNA levels have approximately 10% risk to develop OBI despite antiviral treatment, vaccination and HBIG, but that such OBI confers a minimal long-term risk for overt infection, at least in immunocompetent children.
Literature
1.
go back to reference Global Hepatitis Report 2017. Geneva: World Health Organisation; 2017. License: CC BY-NC-SA 3.0 IGO. Global Hepatitis Report 2017. Geneva: World Health Organisation; 2017. License: CC BY-NC-SA 3.0 IGO.
2.
go back to reference Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health. 2014;6:605–11.PubMedPubMedCentral Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health. 2014;6:605–11.PubMedPubMedCentral
4.
go back to reference Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Taormina Workshop on Occult HBVIFM. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397–408.CrossRefPubMed Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Taormina Workshop on Occult HBVIFM. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397–408.CrossRefPubMed
5.
go back to reference Mulrooney-Cousins PM, Chauhan R, Churchill ND, Michalak TI. Primary seronegative but molecularly evident hepadnaviral infection engages liver and induces hepatocarcinoma in the woodchuck model of hepatitis B. PLoS Pathog. 2014;10(8): e1004332.CrossRefPubMedPubMedCentral Mulrooney-Cousins PM, Chauhan R, Churchill ND, Michalak TI. Primary seronegative but molecularly evident hepadnaviral infection engages liver and induces hepatocarcinoma in the woodchuck model of hepatitis B. PLoS Pathog. 2014;10(8): e1004332.CrossRefPubMedPubMedCentral
6.
go back to reference Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol. 2012;57(3):515–21.CrossRefPubMed Shahmoradi S, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol. 2012;57(3):515–21.CrossRefPubMed
7.
go back to reference Yokoyama K, Kumagai H, Takahashi M, Nagashima S, Okamoto H, Yamagata T. Occult hepatitis B virus infection in immunized children born to carrier mothers. Pediatr Int. 2017;59(9):1010–6.CrossRefPubMed Yokoyama K, Kumagai H, Takahashi M, Nagashima S, Okamoto H, Yamagata T. Occult hepatitis B virus infection in immunized children born to carrier mothers. Pediatr Int. 2017;59(9):1010–6.CrossRefPubMed
8.
go back to reference Hsu HY, Chen HL, Wu JF, Ni YH, Chang KC, Chiang CL, et al. Occult Hepatitis B Virus infection in immunized infants born to untreated and tenofovir-treated highly viremic mothers. Clin Gastroenterol Hepatol. 2021;19(7):1494–6.CrossRefPubMed Hsu HY, Chen HL, Wu JF, Ni YH, Chang KC, Chiang CL, et al. Occult Hepatitis B Virus infection in immunized infants born to untreated and tenofovir-treated highly viremic mothers. Clin Gastroenterol Hepatol. 2021;19(7):1494–6.CrossRefPubMed
9.
go back to reference Eilard A, Andersson M, Ringlander J, Wejstal R, Norkrans G, Lindh M. Vertically acquired occult hepatitis B virus infection may become overt after several years. J Infect. 2019;78(3):226–31.CrossRefPubMed Eilard A, Andersson M, Ringlander J, Wejstal R, Norkrans G, Lindh M. Vertically acquired occult hepatitis B virus infection may become overt after several years. J Infect. 2019;78(3):226–31.CrossRefPubMed
10.
go back to reference Malmstrom S, Berglin-Enquist I, Lindh M. Novel method for genotyping hepatitis B virus on the basis of TaqMan real-time PCR. J Clin Microbiol. 2010;48(4):1105–11.CrossRefPubMedPubMedCentral Malmstrom S, Berglin-Enquist I, Lindh M. Novel method for genotyping hepatitis B virus on the basis of TaqMan real-time PCR. J Clin Microbiol. 2010;48(4):1105–11.CrossRefPubMedPubMedCentral
11.
go back to reference Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60(2):468–76.CrossRefPubMed Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60(2):468–76.CrossRefPubMed
12.
go back to reference Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86.CrossRefPubMed Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86.CrossRefPubMed
13.
go back to reference Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34.CrossRefPubMed Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34.CrossRefPubMed
14.
go back to reference Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus placebo to prevent perinatal transmission of Hepatitis B. N Engl J Med. 2018;378(10):911–23.CrossRefPubMedPubMedCentral Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus placebo to prevent perinatal transmission of Hepatitis B. N Engl J Med. 2018;378(10):911–23.CrossRefPubMedPubMedCentral
15.
go back to reference Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84.CrossRefPubMed Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84.CrossRefPubMed
16.
go back to reference Boucheron P, Lu Y, Yoshida K, Zhao T, Funk AL, Lunel-Fabiani F, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):85–96.CrossRefPubMed Boucheron P, Lu Y, Yoshida K, Zhao T, Funk AL, Lunel-Fabiani F, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):85–96.CrossRefPubMed
17.
go back to reference Elefsiniotis IS, Tsoumakas K, Papadakis M, Vlachos G, Saroglou G, Antsaklis A. Importance of maternal and cord blood viremia in pregnant women with chronic hepatitis B virus infection. Eur J Intern Med. 2011;22(2):182–6.CrossRefPubMed Elefsiniotis IS, Tsoumakas K, Papadakis M, Vlachos G, Saroglou G, Antsaklis A. Importance of maternal and cord blood viremia in pregnant women with chronic hepatitis B virus infection. Eur J Intern Med. 2011;22(2):182–6.CrossRefPubMed
18.
go back to reference Liu Y, Wen J, Chen J, Xu C, Hu Y, Zhou YH. Rare detection of occult hepatitis B virus infection in children of mothers with positive hepatitis B surface antigen. PLoS ONE. 2014;9(11): e112803.CrossRefPubMedPubMedCentral Liu Y, Wen J, Chen J, Xu C, Hu Y, Zhou YH. Rare detection of occult hepatitis B virus infection in children of mothers with positive hepatitis B surface antigen. PLoS ONE. 2014;9(11): e112803.CrossRefPubMedPubMedCentral
19.
go back to reference Weis N, Cowan S, Hallager S, Drose S, Kristensen LH, Gronbaek K, et al. Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark. Scand J Gastroenterol. 2017;52(2):178–84.CrossRefPubMed Weis N, Cowan S, Hallager S, Drose S, Kristensen LH, Gronbaek K, et al. Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark. Scand J Gastroenterol. 2017;52(2):178–84.CrossRefPubMed
20.
go back to reference Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat. 2013;20(11):801–10.CrossRefPubMed Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat. 2013;20(11):801–10.CrossRefPubMed
21.
go back to reference Wu J, He J, Xu H. Global prevalence of occult HBV infection in children and adolescents: a systematic review and meta-analysis. Ann Hepatol. 2024;29(1): 101158.CrossRefPubMed Wu J, He J, Xu H. Global prevalence of occult HBV infection in children and adolescents: a systematic review and meta-analysis. Ann Hepatol. 2024;29(1): 101158.CrossRefPubMed
22.
go back to reference Chen ZX, Gu GF, Bian ZL, Cai WH, Shen Y, Hao YL, et al. Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: a real-world prospective cohort study. J Infect. 2017;75(2):146–54.CrossRefPubMed Chen ZX, Gu GF, Bian ZL, Cai WH, Shen Y, Hao YL, et al. Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: a real-world prospective cohort study. J Infect. 2017;75(2):146–54.CrossRefPubMed
23.
go back to reference Rodriguez Lay LLA, Bello Corredor M, Montalvo Villalba MC, Chibas Ojeda AG, Sariego Frometa S, Diaz Gonzalez M, et al. Hepatitis B virus infection assessed 3 to 18 years after vaccination in Cuban children and adolescents born to HBsAg-positive mothers. Arch Virol. 2017;162(8):2393–6.CrossRefPubMed Rodriguez Lay LLA, Bello Corredor M, Montalvo Villalba MC, Chibas Ojeda AG, Sariego Frometa S, Diaz Gonzalez M, et al. Hepatitis B virus infection assessed 3 to 18 years after vaccination in Cuban children and adolescents born to HBsAg-positive mothers. Arch Virol. 2017;162(8):2393–6.CrossRefPubMed
24.
go back to reference Yao QQ, Dong XL, Wang XC, Ge SX, Hu AQ, Liu HY, et al. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol. 2013;20(2):269–75.CrossRefPubMedPubMedCentral Yao QQ, Dong XL, Wang XC, Ge SX, Hu AQ, Liu HY, et al. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol. 2013;20(2):269–75.CrossRefPubMedPubMedCentral
25.
go back to reference Zhou S, Li T, Allain JP, Zhou B, Zhang Y, Zhong M, et al. Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG-administered infants born to HBsAg positive mothers. J Med Virol. 2017;89(12):2130–7.CrossRefPubMed Zhou S, Li T, Allain JP, Zhou B, Zhang Y, Zhong M, et al. Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG-administered infants born to HBsAg positive mothers. J Med Virol. 2017;89(12):2130–7.CrossRefPubMed
26.
go back to reference Su H, Zhang Y, Xu D, Wang B, Zhang L, Li D, et al. Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China. PLoS ONE. 2013;8(8): e70768.CrossRefPubMedPubMedCentral Su H, Zhang Y, Xu D, Wang B, Zhang L, Li D, et al. Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China. PLoS ONE. 2013;8(8): e70768.CrossRefPubMedPubMedCentral
27.
go back to reference Foaud H, Maklad S, Mahmoud F, El-Karaksy H. Occult hepatitis B virus infection in children born to HBsAg-positive mothers after neonatal passive-active immunoprophylaxis. Infection. 2015;43(3):307–14.CrossRefPubMed Foaud H, Maklad S, Mahmoud F, El-Karaksy H. Occult hepatitis B virus infection in children born to HBsAg-positive mothers after neonatal passive-active immunoprophylaxis. Infection. 2015;43(3):307–14.CrossRefPubMed
28.
go back to reference Hu AQ, Cai QY, Zhang M, Liu HY, Wang TL, Han WH, et al. Overt and occult hepatitis B infection after neonatal vaccination: mother-to-infant transmission and HBV vaccine effectiveness. Int J Infect Dis. 2021;104:601–9.CrossRefPubMed Hu AQ, Cai QY, Zhang M, Liu HY, Wang TL, Han WH, et al. Overt and occult hepatitis B infection after neonatal vaccination: mother-to-infant transmission and HBV vaccine effectiveness. Int J Infect Dis. 2021;104:601–9.CrossRefPubMed
29.
go back to reference Chakvetadze C, Roussin C, Roux J, Mallet V, Petinelli ME, Pol S. Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers. Vaccine. 2011;29(16):2846–9.CrossRefPubMed Chakvetadze C, Roussin C, Roux J, Mallet V, Petinelli ME, Pol S. Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers. Vaccine. 2011;29(16):2846–9.CrossRefPubMed
30.
go back to reference Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652–7.CrossRefPubMed Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652–7.CrossRefPubMed
31.
go back to reference Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773-81.e2.CrossRefPubMed Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773-81.e2.CrossRefPubMed
32.
go back to reference Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. Lancet Infect Dis. 2022;22(8):1181–90.CrossRefPubMed Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. Lancet Infect Dis. 2022;22(8):1181–90.CrossRefPubMed
33.
go back to reference Zhang W, Xu C, Rui Y, Chen J, Chen T, Dai Y, et al. Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. J Virus Erad. 2022;8(2): 100076.CrossRefPubMedPubMedCentral Zhang W, Xu C, Rui Y, Chen J, Chen T, Dai Y, et al. Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers. J Virus Erad. 2022;8(2): 100076.CrossRefPubMedPubMedCentral
Metadata
Title
Occult hepatitis B infection in children born to HBeAg-positive women confers a low long-term risk for HBsAg-positive infection
Authors
Anders Eilard
Maria E. Andersson
Rune Wejstål
Gunnar Norkrans
Magnus Lindh
Publication date
09-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Infection
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-024-02290-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.